Sulfonylureas are an older class of type 2 diabetes therapy but remain the most commonly prescribed antidiabetic drug after metformin. Patients taking metformin for type 2 diabetes (T2D) who switch to ...
Switching therapy from metformin to a sulfonylurea increases the risk for adverse outcomes in patients with type 2 diabetes, new research suggests. Results of a study using data from the UK Clinical ...
Moderate-risk patients with diabetes treated with a sulfonylurea appear to be at a higher risk of major adverse cardiovascular events than those who receive a dipeptidyl peptidase-4 (DPP-4) inhibitor, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results